Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples